Natixis Advisors LLC Lowers Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Natixis Advisors LLC lowered its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 16.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 168,867 shares of the company’s stock after selling 32,485 shares during the quarter. Natixis Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $3,043,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its stake in shares of Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after acquiring an additional 1,031,400 shares during the last quarter. Truist Financial Corp boosted its stake in Teva Pharmaceutical Industries by 7.0% in the 2nd quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock worth $63,135,000 after purchasing an additional 254,483 shares in the last quarter. National Pension Service grew its position in Teva Pharmaceutical Industries by 107.3% during the 3rd quarter. National Pension Service now owns 3,170,640 shares of the company’s stock valued at $57,135,000 after purchasing an additional 1,640,940 shares during the last quarter. Iron Triangle Partners LP increased its stake in Teva Pharmaceutical Industries by 113.1% during the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after purchasing an additional 1,469,864 shares in the last quarter. Finally, Tri Locum Partners LP raised its holdings in Teva Pharmaceutical Industries by 15.1% in the second quarter. Tri Locum Partners LP now owns 2,550,307 shares of the company’s stock worth $41,442,000 after buying an additional 334,119 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.55% of the stock is currently owned by insiders.

Analyst Ratings Changes

TEVA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. UBS Group increased their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays upped their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Trading Up 0.2 %

Teva Pharmaceutical Industries stock opened at $17.12 on Friday. Teva Pharmaceutical Industries Limited has a 52-week low of $9.35 and a 52-week high of $19.31. The company has a market cap of $19.40 billion, a P/E ratio of -20.14, a P/E/G ratio of 1.33 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The business has a 50-day simple moving average of $17.67 and a two-hundred day simple moving average of $17.32.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.